Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage 2

Launched by UNIVERSITY HOSPITAL, CAEN · Jul 3, 2018

Keywords

ClinConnect Summary

This clinical trial, called the Neuropsychological and Brain Medical Imaging Study, is looking at how brain damage affects thinking and behavior. Researchers want to understand specific difficulties that people may experience after having a stroke, brain injury, or certain brain disorders. They will compare two groups: one group of patients with these brain issues and another group of healthy volunteers. The study will use advanced imaging techniques to see what changes occur in the brain and how these relate to cognitive problems.

To participate, you need to be over 17 years old and speak French. Women must be using effective contraception during the study. If you have a history of neurological or psychiatric issues, you may not qualify, especially if you have severe depression or anxiety. Participants will undergo brain imaging tests and cognitive assessments, which means you will be asked to complete some tasks to evaluate your thinking abilities. This study is currently recruiting participants, and it aims to shed light on how brain damage impacts everyday life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 17 years
• • French language
• • Effective contraception for women during the study
• • Informed consent
• • No alcohol intake the day before the exam
• • For patients only, focal cerebral lesion (stroke, malformation, tumor, inflammatory, infectious, traumatic), neonatal pathology, developmental or degenerative disease with cognitive deficit
• Exclusion Criteria:
• • For healthy volunteers: previous neurological history (except non complicated migraine or epilepsy), previous psychiatric history (except depression with good evolution or anxiety), or severe cranial traumatism
• • For patients: vigilance disorders, severe depression or anxiety.
• • For both: psychotropic medication other than a hypnotic or an anxiolytic at low doses without dose modification for at least one month, severe visual or auditory impairment, patient without judicial or administrative liberty, measure of legal protection or no capable to express their consent, pregnancy or breastfeeding, contraindication for MRI or GVS if applicable, participation in another trial or former involvement in another trial within one month.